Rhenman & Partners Asset Management AB boosted its stake in LivaNova PLC (NASDAQ:LIVN) by 26.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 120,600 shares of the company’s stock after buying an additional 25,600 shares during the period. Rhenman & Partners Asset Management AB’s holdings in LivaNova were worth $11,031,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently made changes to their positions in LIVN. FMR LLC lifted its stake in shares of LivaNova by 0.3% in the second quarter. FMR LLC now owns 4,843,407 shares of the company’s stock worth $483,469,000 after acquiring an additional 13,847 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of LivaNova by 65.3% in the second quarter. Bank of America Corp DE now owns 55,764 shares of the company’s stock worth $5,567,000 after acquiring an additional 22,031 shares in the last quarter. United Services Automobile Association lifted its stake in shares of LivaNova by 23.5% in the second quarter. United Services Automobile Association now owns 36,022 shares of the company’s stock worth $3,596,000 after acquiring an additional 6,846 shares in the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of LivaNova by 12.7% in the third quarter. Louisiana State Employees Retirement System now owns 13,300 shares of the company’s stock worth $1,649,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Aperio Group LLC lifted its stake in shares of LivaNova by 14.1% in the third quarter. Aperio Group LLC now owns 13,290 shares of the company’s stock worth $1,648,000 after acquiring an additional 1,645 shares in the last quarter. Institutional investors and hedge funds own 90.41% of the company’s stock.
LIVN has been the topic of several research reports. ValuEngine cut LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 28th. BidaskClub cut LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 22nd. BTIG Research restated a “hold” rating on shares of LivaNova in a research note on Thursday, November 1st. Zacks Investment Research upgraded LivaNova from a “strong sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, UBS Group initiated coverage on LivaNova in a research note on Tuesday, November 27th. They set a “neutral” rating and a $105.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $122.20.
In other news, insider David S. Wise sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $119.23, for a total transaction of $178,845.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $116.68, for a total value of $116,680.00. The disclosure for this sale can be found here. Insiders have sold 7,450 shares of company stock valued at $750,880 over the last ninety days. Corporate insiders own 0.41% of the company’s stock.
NASDAQ:LIVN opened at $92.45 on Monday. The company has a market cap of $4.50 billion, a PE ratio of 27.93, a P/E/G ratio of 2.68 and a beta of 0.87. LivaNova PLC has a 52 week low of $79.96 and a 52 week high of $131.54. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.65 and a quick ratio of 1.21.
ILLEGAL ACTIVITY WARNING: “Rhenman & Partners Asset Management AB Increases Position in LivaNova PLC (LIVN)” was originally published by Zolmax and is the sole property of of Zolmax. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://zolmax.com/investing/rhenman-partners-asset-management-ab-increases-position-in-livanova-plc-livn/2891848.html.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Featured Article: Stock Split
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.